pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Big Pharma · news · pharmadog
← back to Big Pharma
News · Big Pharma
308
stories
3h
9 biotechs will cut at least half their California workforces
biospace
17h
Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B deal
biospace
18h
In China’s shadow, Pfizer CEO calls for AI savings to bolster Big Pharma
biospace
23h
Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna
fiercebiotech
1d
5 acquisitions that forced Big Pharmas to co-parent
biospace
1d
At Fierce’s London event, Big Pharmas tell biotechs to ‘be transparent’ to secure deals
fiercebiotech
1d
AstraZeneca, Calidi, Tempest make significant workforce cuts
biospace
2d
J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
biospace
2d
Biogen inks $411M neurodegeneration pact with protein degrader biotech TrimTech
fiercebiotech
2d
Lilly secures another myelofibrosis option via $1.5B deal for JPM-founded Calytrix
fiercebiotech
3d
Summit's PD-1xVEGF rejected by FDA in lung cancer
biospace
6d
Cellectis will shed 70% of workforce as part of in vivo pivot
fiercebiotech
6d
Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact
fiercebiotech
6d
Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
biospace
6d
Opinion: I research MAHA and Black Americans. The relationship is complicated — and fascinating
stat
6d
BMS reunites R&D divisions under Cristian Massacesi, while Robert Plenge departs
fiercebiotech
7d
2026 Q3 Job Market Report: Job opportunities, layoffs show YOY improvement
biospace
7d
Pfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launch
fiercebiotech
8d
Without US action on China’s innovation blitz, biotech leaders see a Rust Belt future
biospace
8d
Amgen builds Sjögren’s case with detailed phase 3 data ahead of Novartis showdown
fiercebiotech
8d
AstraZeneca buys partner Omniose for bacterial vaccine technology
fiercebiotech
9d
London biotech Oyster harvests $60M for tau-targeting brain drugs
biopharma dive
9d
AbCellera becomes latest biotech to abandon dream of developing OX40 drug
fiercebiotech
9d
Argenx to buy peptide platform in potentially billion-dollar deal
biopharma dive
9d
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
biospace
9d
Argenx buyout of peptide engine and Big Pharma favorite UNP could top $1B
biospace
12d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
12d
‘Flying blind’: Why experts fear Treasury’s China biotech investment crackdown will backfire
fiercebiotech
12d
Sarepta’s new CEO confident in clinical execution as DMD competitors close in
biospace
12d
Moderna’s norovirus vaccine plans in limbo in wake of phase 3 miss
fiercebiotech
← prev
page 1 of 11
next →